Urogenital microbiota: the spectrum of mycosis or urinary tract infections after each antibiotic treatment

Drug

Urology

A vicious circle. Vaginal tract infections such as vulvovaginal candidiasis often appear after antibiotic therapy, and sometimes following the administration of antibiotics commonly used to treat those same infections. The situation is no better for urinary tract infections: antibiotics typically used to treat them have become a risk factor for their occurrence.

About this article

Author

Dr. Jean-Marc Bohbot

Created 25 August 2021

Updated 29 August 2024

Historically, until recent scientific work, urine was regarded as sterile. Compared to other microbiota, this ecosystem has low biomass.¹ While a consensus regarding the precise composition has yet to be reached, around 100 species have been identified from 4 principal phyla (Proteobacteria, Firmicutes, Actinobacteria, and Bacteroidetes).² And though the role of the urinary microbiota is currently a matter of debate, it is well understood that diminished diversity seems to be a risk factor for urinary tract infections.

Yet, the vaginal microbiota gains on the other hand from having low diversity and being largely dominated by lactobacilli.³ Despite considerable variability among women, 5 community state types (CST) have been described in the vaginal flora: 4 dominated by one or several species of the Lactobacillus genus (L. crispatus, L. gasseri, L. iners or L. jensenii) and one polymicrobial.⁴ In both cases, dysbiosis following antibiotic treatment may increase the risk of infection.⁵

A spectrum of fungus at each antibiotic treatment

This is what many women being treated with antibiotics dread: developing post-antibiotic vulvovaginal candidiasis. This anxiety is more than justified: antibacterial therapy, whether systemic or applied locally to the vagina, is thought to be one of the main factors leading to vulvovaginal candidiasis.⁵ This infection may be associated with vaginal microbiota disruption together with Candida yeast proliferation (C. albicans in the majority of cases ; Figure 3). The most common clinical signs of this infection are vulvar pruritus, a burning sensation accompanied by vaginal pain or irritation that may lead to dyspareunia or dysuria.⁶

FIGURE 3. Yeast proliferation induced by antibiotics exposure

Urinary tract infections: what to prescribe?

According to the 2017 update of the German clinical guidelines on managing uncomplicated urinary tract infections in adult patients:⁹

“For the treatment of acute uncomplicated cystitis (AUC), fosfomycin-trometamol, nitrofurantoin, nitroxoline, pivmecillinam, and trimethoprim (depending on the local rate of resistance) are all equally recommended. Cotrimoxazole, fluoroquinolones, and cephalosporins are not recommended as antibiotics of first choice, due to concerns over the possibility of an unfavorable impact on the microbiome.
For AUC with mild to moderate symptoms, instead of antibiotics, symptomatic treatment alone may be considered depending on the patient’s preference after discussing possible adverse events and outcomes.
Primarily non-antibiotic options are recommended for prophylaxis of recurrent urinary tract infections.”

The vicious circle of bacterial vaginosis

Though the etiology of bacterial vaginosis (BV), the main form of vaginal infection, remains unclear, it is believed that antibiotic-induced dysbiosis could be partly responsible for its development: dominant lactobacilli are supplanted by polymicrobial flora derived from numerous bacterial genera (Gardnerella, Atopobium, Prevotella, etc.). A vicious circle could be initiated: though antibiotics can be used to treat BV, they are also, alongside sexual history, vaginal douching, contraceptive use, age, stage in the menstrual cycle, tobacco use, etc., among the numerous risk factors associated with this type of infection.⁷

Urinary microbiota: a textbook case of antibiotic resistance

Urinary tract infections (UTI) affect millions of men (a 3% annual incidence rate in the US) and women (10%) every year.⁸ Recurrent UTIs contribute greatly to this incidence: notwithstanding their receiving appropriate antibiotic therapy, more than 30% of women will experience a subsequent infection within the following 12 months.⁸ UTIs are becoming increasingly difficult to treat because of the rapid spread of drug resistance among Gram-Negative organisms, notably UPEC (uropathogenic Escherichia coli) which cause approximately 80% of UTIs.⁸

Paradoxically, broadspectrum antibiotics used to treat both community acquired and hospital-associated UTIs have become a risk factor for their occurrence.⁸ Mechanisms involving both gut and vaginal microbiota are suspected: in the gut, the ultimate reservoir for UPEC, antibiotic exposure increases inflammation and promotes the proliferation of E. coli; in the vagina, they diminish colonization by Lactobacillus species that suppress vaginal UPEC invasion and subsequent bacterial ascension from the vagina into the urinary tract. This is the reason why, experts nowadays recommend that they should be used with caution and that microbiota-sparing treatments should be developed.⁸

Dr. JEAN-MARC BOHBOT, MD, PhD. Andrologist and Infectious Diseases Specialist, Institut Alfred Fournier, Paris (France)

Clinical case

by Dr. Jean-Marc Bohbot, MD, PhD

18-year-old Solène consults for recurrent vulvo-vaginal candidiasis. For about 3 months, she suffers from recurrent candidiasis (2 episodes per month) with abundant white leucorrhea and intense vulvo-vaginal pruritus. These episodes have a very negative impact on her daily life, not to mention her sex life.
A vaginal sample confirmed the presence of Candida albicans with an intermediate vaginal microbiota (Nugent score 6). Solène has a regular partner who experiences no symptoms. She is not diabetic. The candidiasis appeared a few weeks after starting a daily antibiotic treatment (cyclines) for acne. These antibiotics promote vaginal dysbiosis and facilitate the development of fungi.
After consultation with the dermatologist, oral cyclines were replaced by a local treatment; the candidiasis disappeared within 2 weeks.

In cases of acne, the use of antibiotics should be limited or should be accompanied by probiotic cures to preserve the balance of the vaginal microbiota.

Sources

^{1 Neugent ML, Hulyalkar NV, Nguyen VH, et al. Advances in Understanding the Human Urinary Microbiome and Its Potential Role in Urinary Tract Infection. mBio. 2020 Apr 28;11(2):e00218-20.}

^{2 Morand A, Cornu F, Dufour JC, et al. Human Bacterial Repertoire of the Urinary Tract: a Potential Paradigm Shift. J Clin Microbiol. 2019 Feb 27;57(3). pii: e00675-18.}

^{3 Gupta S, Kakkar V, Bhushan I. et al. Crosstalk between Vaginal Microbiome and Female Health: A review. Microb Pathog. 2019 Aug 23;136:103696.}

^{4 Greenbaum S, Greenbaum G, Moran-Gilad J, et al. Ecological dynamics of the vaginal microbiome in relation to health and disease. Am J Obstet Gynecol. 2019;220(4):324-335.}

^{5 Shukla A, Sobel JD. Vulvovaginitis Caused by Candida Species Following Antibiotic Exposure. Curr Infect Dis Rep. 2019 Nov 9;21(11):44.}

^{6 Gonçalves B, Ferreira C, Alves CT, et al. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit Rev Microbiol. 2016 Nov;42(6):905-27.}

^{7 Coudray MS, Madhivanan P. Bacterial vaginosis-A brief synopsis of the literature. Eur J Obstet Gynecol Reprod Biol. 2019 Dec 24;245:143-148.}

^{8 Klein RD, Hultgren SJ. Urinary tract infections: microbial pathogenesis, host-pathogen interactions and new treatment strategies. Nat Rev Microbiol. 2020;18(4):211-226.}

^{9 Kranz J, Schmidt S, Lebert C, et al. The 2017 Update of the German Clinical Guideline on Epidemiology, Diagnostics, Therapy, Prevention, and Management of Uncomplicated Urinary Tract Infections in Adult Patients. Part II: Therapy and Prevention. Urol Int. 2018;100(3):271-278.}